

CV - Jens D. Lundgren, MD, DMSc, Professor, Chief Physician, Director

Work: Centre for Viral Diseases, Department of Infectious Diseases, National University Hospital, 2100 Copenhagen Ø, Denmark
Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, Panum Institute bldg 21.1, Blegdamsvej 3 B, 2200 Copenhagen N, Denmark

E-mail: jdl@cphiv.dk

Education and previous employment

1987 Graduated from University of Copenhagen as medical doctor (M.D.)
1987-1989 Fogerty Research Fellow, Clinical Center, NIH, Bethesda, Maryland, USA
1989-1991 Staff Physician, Hvidovre University Hospital
1992 Doctor of Medical Sciences (DMSc), University of Copenhagen
1991-1993 Residency in internal medicine
1993-1998 Attending Physician, Hvidovre Univ. Hospital, Frederiksberg Hospital and State Univ. Hospital
1995 Specialist in internal medicine
1996 Specialist in infectious diseases
1997 Specialist in tropical medicine
1998-2007 Chief Physician, Hvidovre University Hospital, Denmark
2005-2007 Professor of infectious disease epidemiology, University of Copenhagen

Current employment

1998- Director of Copenhagen HIV Programme (CHIP), Univ of Copenhagen & State Univ. Hospital
2007- Professor of Viral Diseases, University of Copenhagen, Faculty of Health Sciences
2007- Chief physician, State University Hospital, Copenhagen

Honours

2005 - Member of American Society for Clinical Investigation (ASCI)
2005 - Honorary lifetime member, Intern. Ass. of Physicians in AIDS Care (IAPAC)
2005 - Honorary lifetime member, Polish AIDS Society
2010 - Member of Association of American Physicians (AAP)

International Science

1994 - EuroSIDA cohort study (www.euro sida.org), Principal investigator
1999 - "Data collection on Adverse events of anti-HIV Drugs" (D:A:D): Chair, steering committee
2000 - Europ. AIDS Clinical Society (EACS): Exec. Committee member; chair of guidelines panel
2005 - HIV Medicine: Co-editor-in-chief; member of editorial board of several journals
2006 - INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) www.insight.cabr.umn.edu: Member Exec. Comm.; 2010-, Chair, Scientific Steering Committee,
2007 - HIV in Europe (www.hiveurope.eu): Co-chair, steering committee,
2009 - Strategic Timing of AntiRetroviral Treatment (START) Protocol: Co-chair
Multiple invitations for plenary speaker at international medical conferences.
Current research grant awards: European Commission (EuroSIDA (FP6), NEAT (FP6), CHAIN (FP7), WHO (FP7), EuroCoord (FP7)), HAART Oversight Committee – consortium initiated by the European Medicines Agency (EMA)(for D:A:D), NIAID, NIH (INSIGHT)

Supervision of PhD/DMSc students: 15 successfully completed and 3 ongoing

H-index: 53 (= number of articles with ≥ 35 citations)

Average citations per item: 35.69

Total citations: 11,422

Original articles: 320

Selected references:

- Interleukin-2 therapy in patients with HIV infection.** *INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.* N Engl J Med. 2009;361(16):1548-59.
- The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients.** *Jensen JU, Lundgren B, Hein L, Mohr T, Petersen PL, Andersen LH, Lauritsen AO, Hougaard S, Mantoni T, Bømler B, Thornberg KJ, Thormar K, Løken J, Steensen M, Carl P, Petersen JA, Tousi H, Søre-Jensen P, Bestle M, Hestad S, Andersen MH, Fjeldborg P, Larsen KM, Rossau C, Thomsen CB, Ostergaard C, Kjaer J, Grarup J, Lundgren JD.* BMC Infect Dis. 2008 Jul 13;8:91.
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection.** *LH Kuller, R Tracy, W Belloso, SD Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, J Neuhaus, D Nixon, NI Paton, JD Neaton for the INSIGHT SMART Study Group.* PLoS Med. 2008 Oct 21;5(10):e203.
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.** Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E I Sadr, F Dabis, S De Wit, M Law, A D´Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren. Lancet. 2008 371(9622):1417-26.
- Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.** *AN Phillips, D Pillay, AH Miners, DE Bennett, CF Gilks, JD Lundgren.* Lancet. 2008;371(9622):1443-51
- Class of Antiretroviral Drugs and the Risk of Myocardial Infarction.** *N Friis-Møller, P Reiss, CA Sabin, R Weber, A D´Arminio Monforte, W El-Sadr, R Thiebaut, S de Wit, O Kirk, E Fontas, MG Law, A Phillips, JD Lundgren on behalf of the D:A:D study group.* N Engl J Med. 2007;356:1723-35
- CD4+ Count-Guided Interruption of Antiretroviral Treatment. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.** *WM El-Sadr, JD Lundgren, JD Neaton, F Gordin, D Abrams, RC Arduino, A Babiker, W Burman, N Clumeck, CJ Cohen, D Cohn, D Cooper, S Emery, G Fätkenheuer, B Gazzard, B Grund, J Hoy, K Klingman, M Losso, N Markowitz, J Neuhaus, AN Phillips, and C Rappoport.* N Engl J Med 2006;355(22); 2283-2296
- A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.** *Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD; COLATE study group.* Antivir Ther. 2006;11(6):761-70.
- A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.** *Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD; MaxCmin2 Trial Group.* Antivir Ther. 2005;10(6):735-43.
- Predictors of CD4 Count Trend and Mortality among HIV-1 - Infected Persons with Virologic Failure to all Three Antiretroviral Drug Classes.** *The Plato Collaboration, Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe, Gill J, Castelli F, Phillips AN.* Lancet 2004;364: 51–62
- Combination antiretroviral therapy and the risk of myocardial infarction.** *Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; for the DAD study group.* N Engl J Med. 2003;349:1993-2003.
- Continued decline in the AIDS and death rates in the EuroSIDA study : 1994 – 2002.** *A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, A d'Arminio Monforte, B Knysz, M Dietrich, A Phillips, JD Lundgren for the EuroSIDA study group.* Lancet 2003;362:22-9.
- Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.** *Ledergerber, B., Mocroft, A., Reiss, P., Furrer, H., Kirk, O., Bickel, M., Uberti-Foppa, C., Pradier, C., d'Arminio, Monforte A., Schneider, M. M., and Lundgren, J. D.* N.Engl.J.Med. 2001;344(3):168-174.
- AIDS across Europe, 1994-98: the EuroSIDA study.** *Mocroft, A., Katlama, C., Johnson, A. M., Pradier, C., Antunes, F., Mulcahy, F., Chiesi, A., Phillips, A. N., Kirk, O., and Lundgren, J. D.* Lancet. 2000;356(9226):291-296.
- Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.** *Mocroft, A., Vella, S., Benfield, T. L., Chiesi, A., Miller, V., Gargalianos, P., d'Arminio, Monforte A., Yust, I., Bruun, J. N., Phillips, A. N., and Lundgren, J. D.* Lancet. 1998;352(9142):1725-1730.
- Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.** *Lundgren, J. D., Phillips, A. N., Pedersen, C., Clumeck, N., Gatell, J. M., Johnson, A. M., Ledergerber, B., Vella, S., and Nielsen, J. O.* JAMA. 1994;271(14):1088-1092.
- Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion.** *Lundgren, J. D., Davey, R. T., Jr., Lundgren, B., Mullol, J., Marom, Z., Logun, C., Baraniuk, J., Kaliner, M. A., and Shelhamer, J. H.* J.Allergy Clin.Immunol. 1991;87(3):689-698.